Astex Pharmaceuticals
Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. As part of Japan's leading pharmaceutical company, Otsuka Pharmaceutical Co. Ltd., Astex operates from two sites with drug discovery research headquarters in Cambridge, UK and clinical development headquarters in Pleasanton, California, USA.
We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Although our discovery platform has been successfully applied to therapeutic targets addressing a variety of disease areas, our primary clinical area of focus is currently cancer. In addition, we are expanding our capabilities and building expertise in the area of fragment-based drug discovery for diseases of the CNS which we plan to develop through collaboration with our parent company, Otsuka, or with other pharmaceutical company partners.
Contact Astex Pharmaceuticals via their website
News Archives
14/04/2021 Astex Pharmaceuticals reports NCCN Projects to Study Oral Decitabine and Cedazuridine...more
28/10/2020 Astex Pharmaceuticals CRADA with U.S. National Cancer Institute...more
14/10/2020 Astex and Otsuka announce phase 3 ASTRAL trial studies results...more
08/09/2020 Astex Pharmaceuticals and MD Anderson Announce Strategic Collaboration...more
31/08/2020 Astex Pharmaceuticals Announces ASTX660 Granted FDA Orphan Drug Designation...more
07/07/2020 Astex Pharmaceuticals announces FDA and Health Canada approval of INQOVI®...more
11/02/2020 Astex Pharmaceuticals announces FDA acceptance for NDA review of ASTX727...more
09/12/2019 Astex Pharmaceuticals presents topline phase 3 study data...more
03/09/2019 Astex Pharmaceuticals announces ASTX727 granted FDA orphan drug designation...more
07/06/2019 Taiho Oncology to Commercialize Astex Pharmaceuticals’ Drug Candidates ...more
07/06/2019 British Company Behind Groundbreaking Breast Cancer Treatment ...more
06/06/2019 Astex Pharmaceuticals and Otsuka announce ASTX727 study results ...more
12/04/2019 BALVERSA™ discovered by Astex and Janssen receives FDA approval...more
09/05/2018 Astex's Harren Jhoti Made Fellow of the Royal Society...more
15/03/2018 Astex announces US FDA Breakthrough Therapy Designation for erdafitinib...more
26/01/2018 Astex Pharmaceuticals' Harren Jhoti Receives Lifetime Achievement Award from BIA...more
19/01/2018 Astex Pharmaceuticals: Otsuka Signs Women's Empowerment Statement...more
24/08/2017 Astex Pharmaceuticals Celebrates as Cancer Drug Receives European Marketing Approval...more
13/03/2017 Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval...more
21/11/2016 Astex Joins the Dementia Discovery Fund as a Strategic Investor...more
14/10/2016 Astex scientist, Alison Woolford, Wins Capps Green Zomaya Award...more
19/04/2016 Astex Pharmaceuticals Enters Clinical Trial Collaboration...more
06/10/2015 Astex Pharmaceuticals Announces Orphan Drug Designation for Guadecitabine...more
01/09/2015 Open Innovation Article Features Astex Pharmaceuticals President and CEO ...more
18/08/2015 Astex Pharmaceuticals Announces Key Clinical Data Published in Lancet Oncology...more
16/06/2014 Astex Pharmaceuticals Presents Final Results of Phase 2 SGI-110 Study...more
04/03/2014 Astex Earns Milestone Payment on Initiation of Phase 3 Study...more
11/10/2013 Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals...more
05/09/2013 Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals for $8.50 Per Share in Cash...more
28/08/2013 Astex Pharmaceuticals Announces Topline Results Phase 2 Study...more
22/07/2013 Astex Pharmaceuticals Announces HSP90 Inhibitor AT13387 First Data...more
08/07/2013 Astex Pharmaceuticals Announces IND Candidate: ASTX727...more
20/06/2013 Astex Pharmaceuticals will present updated SGI-110 data at European Cancer Congress...more
14/06/2013 Astex Pharmaceuticals Announces Presentation of Updated SGI-110-01 Study Results...more
10/04/2013 Astex Pharmaceuticals Provides SGI-110 Update...more
16/01/2013 Astex Pharmaceuticals collaborators launch clinical trial to treat several cancer types...more
29/10/2012 Astex Pharmaceuticals Signs Strategic Drug Discovery Alliance...more
09/10/2012 Astex Pharmaceuticals Earns $5 Million for First Commercial Sale of DACOGEN®...more
04/10/2012 Astex Pharmaceuticals President Harren Jhoti elected to UK BioIndustry Association Board...more
02/10/2012 Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial...more
28/09/2012 DACOGEN® Approved in the European Union for the Treatment of Acute Myeloid Leukemia...more
10/09/2012 Astex Pharmaceuticals Announces Clinical Trial in Prostate Cancer Patients...more
07/09/2012 Astex and ICR in Epigenetic Discvery Collaboration...more
20/08/2012 Astex Pharmaceuticals Award for New Technologies in Drug Discovery...more
22/06/2012 Astex Pharmaceuticals Announces Phase 2 Expansion of SGI-110 Clinical Trial...more
13/06/2012 Astex Pharmaceuticals Earns $5.4 Million Milestone...more
03/01/2012 Astex Pharmaceuticals to Present at Biotech Showcase on January 9th...more
